Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2001-10-23
2009-02-03
O'Hara, Eileen B (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S139100, C514S002600
Reexamination Certificate
active
07485301
ABSTRACT:
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5652133 (1997-07-01), Murphy
patent: 6329159 (2001-12-01), Andrew et al.
patent: 6503735 (2003-01-01), Wei et al.
patent: 6723520 (2004-04-01), Wang et al.
patent: 6939885 (2005-09-01), Ungashe et al.
patent: 2003/0018167 (2003-01-01), Wang et al.
patent: 2005/0165067 (2005-07-01), Ungashe et al.
patent: WO 97/48807 (1997-12-01), None
patent: WO 98/01557 (1998-01-01), None
patent: WO 98/32858 (1998-07-01), None
Salmi et al. J Clin Invest. 99(9), 2165-2172, 1997.
Podolsky et al. J Clin Invest 92, 372-380, 1992.
Murdoch et al. Blood, 95(10): 3032-3043, 2000.
Attwood et al. Science 290, 471, 2000.
Scolnik et al. Trends in Biotech 18(1): 34-9, 2000.
Ward et al. Therap. Immunol 1: 165-171, 1994.
Kahan, Curr Opin Immunol 4:553-560, 1992.
Toy et al. J Clin Invest 100(8): 2062-2071, 1997.
Chiodini Clin Micro Review 2(1): 90-117, 1989.
Sandborn, Review Gastro Disorder 4(3): 525-533, 2004.
Su et al, J Clin Invest 104(4): 383-389, 1999.
Mitsuyama et al. Digestion 63(1): 68-72, 2001.
Metzler et al, Nat Struc Biol 4:527-531, 1997.
Taneja et al. Nature Immunology, 2001, vol. 2 (9):781-784.
Hoffmann et al., Pathobiology, 2002, vol. 70(3):121-130.
Huang, Z., “Structural Chemistry and Therapeutic Intervention of Protein-Protein Interactions in Immune Response, Human Immunodeficiency Virus Entry, and Apoptosis,”Pharmacology&Therapeutics, 86: 201-215 (2000).
Zlotnick, A., and Yoshie, O., “Chemokines: A New Classification System and Their Role in Immunity,”Immunity, 12(2): 121-127 (2000).
Mackay, C.R., “Chemokines: Immunology's High Impact Factors,”Nature Immunology, 2(2): 95-101 (2001).
ATCC Accession No. CRL-1582, “MOLT-4”, In:Catalogue of ATCC Cell Lines and Hybridomas, 7th Edition, (Rockville, MD: American Type Culture Collection), p. 149 (1992).
Yoshida, R., et al., “Molecular Cloning of a Novel Human CC Chemokine EBI1-ligand Chemokine That is a Specific Functional Ligand for EBI1, CCR7,”The Journal of Biological Chemistry, 272(21):13803-13809 (1997).
Baba, M., et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC,”The Journal of Biological Chemistry, 272(23):14893-14898 (1997).
Imai, T., et al., “The T Cell-directed CC Chemokine TARC is a Highly Specific Biological Ligand for CC Chemokine Receptor 4,”The Journal of Biological Chemistry, 272(23):15036-15042 (1997).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3,”The Journal of Biological Chemistry, 271(13):7725-7730 (1996).
Vicari, A.P., et al., “TECK: A Novel CC Chemokine Specifically Expressed by Thymic Dendritic Cells and Potentially Involved in T Cell Development,”Immunity, 7:291-301 (1997).
Damon, I., et al., “Broad Spectrum Chemokine Antagonistic Activity of a Human Poxvirus Chemokine Homolog,”Proc. Natl. Acad. Sci. USA, 95:6403-6407 (1998).
O'Garra, A., et al., “T-cell Subsets: Chemokine Receptors Guide the Way,”Current Biology, 8:R646-R649 (1998).
Kim, C.H., et al., “Chemokines: Signal Lamps for Trafficking of T and B Cells for Development and Effector Function,”J. Leukoc. Biol., 65:6-15 (1999).
Murphy, P.M., “The Molecular Biology of Leukocyte Chemoattractant Receptors,”Annu. Rev. Immunol., 12:593-633 (1994).
Zlotnik, A., et al., “Recent Advances in Chemokines and Chemokine Receptors,”Critical Reviews™ in Immunology, 19:1-47 (1999).
Nomiyama, H., et al., “The Human CC Chemokine TECK (SCYA25) Maps to Chromosome 19p13.2,”Genomics, 51:311-312 (1998).
Vicari, A.P., et al., “TECK: A Novel CC Chemokine Associated with T-Cell development,”J. Allergy Clin. Immunol., 99(1):S246, Abstract No. 1003, (1997).
Combadiere, C., et al., “Cloning and Functional Expression of Two Human CC Chemokine Receptors,”FASEB J.10(6):A1093 Abstract No. 545, (1996).
Gao, J.-L., et al., “Cloning and Expression of the Mouse MIP-1α Receptor Gene and Two Related Genes,”9thInternational Congress of Immunology, p. 108, Abstract No. 637 (1995).
GenBank Accession No. U45982, “Human G Protein Coupled Receptor GPR-9-6 Gene, Complete CDS,” (1996).
Zaballos, A., et al., “Cutting Edge: Identification of the Orphan Chemokine Receptor GPR-9-6 as CCR9, the Receptor for the Chemokine TECK,”J. Immunol., 162(10):5671-5675 (1999).
Chuntharapai, A. and Kim, K.J., “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Locati M. et al., “Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS,”Annu. Rev. Med.50:425-440 (1999).
Zabel, B.A. et al., “Human G Protein-coupled Receptor GPR-9-6/CC Chemokine Receptor 9 is Selectively Expressed on Intestinal Homing T Lymphoctyes, Mucosal Lymphocytes, and Thymocytes and is Required for Thymus-expressed Chemokine-mediated Chemotaxis,”J. Exp. Med190(9):1241-1255 (1999).
Swissprot Database, Accession No. P51686, “Probable G-Protein-Coupled Receptor GPR-9-6” [online], Oct. 1996.
Nibbs, R.J.B., et al., “Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6,”J. Biol. Chem., 272(51):32078-32083 (1997).
Murphy, P.M., et al., “International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors,”Pharmacol. Rev., 52(1):145-176 (2000).
Youn, B-S, et al., “TECK an Efficacious Chemoattractant for Human Thymocytes, Uses GPR-9-6/CCR9 as a Specific Receptor,”Blood, 94(7):2533-2536 (1999).
Attwood, T.K., “The Babel of Bioinformatics,”Science, 290:471-473 (2000).
Hosoe, N., et al., “Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa,”Am. J. Physiol. Gastrointest. Liver Physiol., 286: G458-G466 (2004).
Ohtsuka, Y., et al., “MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine,”GUT, 49: 526-533 (2001).
Salcedo, R., et al., “Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression,”Blood, 96(1): 34-40 (2000).
Zagorski, J., and Wahl, S. M., “Inhibition of Acute Peritoneal Inflammation in Rats by a Cytokine-Induced Neutrophil Chemoattractant Receptor Antagonist,”The Journal of Immunology, 159: 1059-1062 (1997).
Cunningham, B. C., and Wells, J. A., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science244: 1081-1085 (1989).
Rivera-Nieves, J., et al., “Antibody Blockade of CCL25/CCR9 Ameliorates Early but not Late Chronic Murine Ileitis,”Gastroenterology131: 1518-1529 (2006).
Ngo, J.T., et al., “Computational Complexity, Protein Structure Prediction, and the Levinthatl Paradox,”The Protein Folding Problem and Tertiary Structure Prediction: 491-495 (1994).
Atwood, T.K., “The Babel of Bioinformatics,”Science290: 471-473 (2000).
Skolnick, J., et al., “From Genes to Protein Structure and Function: Novel Applicat
Andrew David P.
Ponath Paul D.
Zabel Brian A.
Kim Yunsoo
Millennium Pharmaceuticals Inc.
O'Hara Eileen B
LandOfFree
Methods of treating inflammatory disease using antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating inflammatory disease using antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating inflammatory disease using antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117266